Notwithstanding many setbacks, a number of MDM2 inhibitors have now progressed into late-stage medical growth. New tactics have also been formulated to improve the efficacy of MDM2 inhibitors also to mitigate their on-concentrate on toxicity. In this evaluation, we summarize the progress and problems in the development of a MDM2 focused therapy.Pro